Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MAIA Biotechnology, Inc.MAIA · Entity 6919 | Chief Scientific Officer | June 01, 2026 | June 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MAIA Biotechnology, Inc.
Report date June 01, 2026 · Filed June 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 46,511 |
Reported balance
After 2026-06-01 transaction · row 1
1 source rowRow 1 · 2026-06-01 · Purchase · Acquired 2,000 · Balance 46,511 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2026 Filed Jun 2, 2026 13:00 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 2,000 | $1.35 | $2,690.00 |
DisclosureSEC source: 0001878313-26-000060 · form4.xml · nonDerivative · entry 1 Gryaznov Sergei · CIK 0001913228 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,511 Read SEC document |
| May 29, 2026 Filed Jun 1, 2026 12:51 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 400,000 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0001878313-26-000051 · form4.xml · derivative · entry 1 Gryaznov Sergei · CIK 0001913228 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2036-05-29 F1 · derivative.exercise_date: The stock options, granted on May 29, 2026 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversary date of the grant and the remaining options to vest ratably monthly thereafter for 36 months. Read SEC document |
| April 10, 2026 Filed Apr 14, 2026 12:44 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 400,000 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0001878313-26-000046 · form4.xml · derivative · entry 1 Gryaznov Sergei · CIK 0001913228 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2036-04-10 F1 · derivative.exercise_date: The stock options, granted on April 10, 2026 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversary date of the grant and the remaining options to vest ratably monthly thereafter for 36 months. Read SEC document |
| May 14, 2025 Filed May 16, 2025 20:14 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 200,000 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0001127602-25-014669 · form4.xml · derivative · entry 1 Gryaznov Sergei · CIK 0001913228 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2035-05-14 F1 · derivative.exercise_date: The stock options, granted on May 14, 2025 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversary of the date of the grant and the remaining options to vest ratably monthly thereafter for 36 months. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:11 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 200,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001127602-25-004350 · form4.xml · derivative · entry 1 Gryaznov Sergei · CIK 0001913228 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2035-02-10 F1 · derivative.exercise_date: The stock options, granted on February 10, 2025 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversary of the date of the grant and the remaining options to vest ratably monthly thereafter for 36 months. Read SEC document |
| April 26, 2024 Filed Apr 30, 2024 21:05 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 141,000 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001127602-24-013658 · form4.xml · derivative · entry 1 Gryaznov Sergei · CIK 0001913228 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,000 Underlying: Common Stock · 141,000 shares Expires 2034-04-26 F1 · derivative.exercise_date: The stock options, granted on April 26, 2024 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversay of the date of the grant and the remaining options to vest ratably monthly thereafter for 36 months. Read SEC document |
| January 24, 2024 Filed Jan 26, 2024 21:10 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 100,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001127602-24-002276 · form4.xml · derivative · entry 1 Gryaznov Sergei · CIK 0001913228 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-01-24 F1 · derivative.exercise_date: The stock options, granted on January 24, 2024 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversary of the date of the grant and the remaining options to vest ratably monthly thereafter for 36 months. Read SEC document |
| May 31, 2023 Filed Jun 5, 2023 21:17 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 75,982 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001127602-23-017879 · form4.xml · derivative · entry 1 Gryaznov Sergei · CIK 0001913228 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,982 Underlying: Common Stock · 75,982 shares Expires 2032-05-30 F1 · derivative.exercise_date: The stock options, granted on May 31, 2023 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| March 08, 2023 Filed Mar 10, 2023 22:12 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 100,000 | $0.00 Strike: $4.10 | $0.00 |
DisclosureSEC source: 0001127602-23-009775 · form4.xml · derivative · entry 1 Gryaznov Sergei · CIK 0001913228 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-03-08 F1 · derivative.exercise_date: The stock options, granted on March 8, 2023 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversary of the date of grant and the remaining options to vest ratably monthly thereafter for 36 months. Read SEC document |
| December 07, 2022 Filed Dec 8, 2022 22:36 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | Exercise / conversionStock Options · Derivative | 10,000 | $0.00 Strike: $1.83 | $0.00 |
DisclosureSEC source: 0001127602-22-027093 · form4.xml · derivative · entry 2 Gryaznov Sergei · CIK 0001913228 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 10,000 shares Expires 2031-04-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Represents an option to purchase shares of Common Stock granted pursuant to the 2020 Equity Incentive Plan. These options vest in 36 equal monthly instalments beginning on January 1, 2021. Read SEC document |
| December 07, 2022 Filed Dec 8, 2022 22:36 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | Exercise / conversionCommon Stock | 10,000 | $1.83 | $18,300.00 |
DisclosureSEC source: 0001127602-22-027093 · form4.xml · nonDerivative · entry 1 Gryaznov Sergei · CIK 0001913228 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,511 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 16, 2022 Filed Sep 20, 2022 15:21 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 100,000 | $0.00 Strike: $3.56 | $0.00 |
DisclosureSEC source: 0001127602-22-022740 · form4.xml · derivative · entry 1 Gryaznov Sergei · CIK 0001913228 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-09-16 F1 · derivative.exercise_date: The stock options, granted on September 16, 2022 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversary of the date of grant and the remaining options to vest ratably monthly thereafter for 36 months. Read SEC document |
| August 24, 2022 Filed Aug 25, 2022 20:47 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | Exercise / conversionStock Options · Derivative | 10,000 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0000899243-22-029752 · doc4.xml · derivative · entry 2 Gryaznov Sergei · CIK 0001913228 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,000 Underlying: Common Stock · 10,000 shares Expires 2029-11-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Represents the right to buy shares of Common Stock granted pursuant to the 2018 Stock Option Plan. These options vested in four equal monthly installments beginning on December 1, 2019. Read SEC document |
| August 24, 2022 Filed Aug 25, 2022 20:47 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | Exercise / conversionCommon Stock | 10,000 | $1.80 | $18,000.00 |
DisclosureSEC source: 0000899243-22-029752 · doc4.xml · nonDerivative · entry 1 Gryaznov Sergei · CIK 0001913228 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,511 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 01, 2022 Filed Aug 2, 2022 22:33 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 3,000 | $5.00 | $15,000.00 |
DisclosureSEC source: 0000899243-22-027455 · doc4.xml · nonDerivative · entry 1 Gryaznov Sergei · CIK 0001913228 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,511 F1 · kind: These shares were purchased by the reporting person in the issuer's initial public offering, which closed on August 1, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.